Opus Genetics (IRD) Cash from Investing Activities (2010 - 2024)
Opus Genetics (IRD) posted quarterly Cash from Investing Activities of $1.2 million for Q4 2024, up 1310.0% quarter-over-quarter from -$100000.0 in Q4 2021.
Powered by 
Analysis
Opus Genetics (IRD) Cash from Investing Activities (2010 - 2024) Analysis & Trends
Opus Genetics (IRD) has reported Cash from Investing Activities for 13 consecutive years, with $1.2 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Cash from Investing Activities changed N/A year-over-year to $1.2 million; the TTM figure through Sep 2025 stood at $1.2 million (changed N/A YoY), while the FY2024 annual figure was $1.2 million, changed N/A from the prior year.
- Cash from Investing Activities climbed to $1.2 million in Q4 2024 per IRD's latest filing, from -$100000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $1.2 million in Q4 2024 and bottomed at -$100000.0 in Q4 2021.
- Historically, Cash from Investing Activities has averaged $549666.7 across 3 years, with a median of $539000.0 in 2020.
- Annual changes were most pronounced in 2020 — Cash from Investing Activities soared 536.26% — and 2021, when it slumped 118.55%.
- Opus Genetics' Cash from Investing Activities stood at $539000.0 in 2020, then plunged by 118.55% to -$100000.0 in 2021, then surged by 1310.0% to $1.2 million in 2024.
- Business Quant data shows IRD's Cash from Investing Activities at $1.2 million in Q4 2024, -$100000.0 in Q4 2021, and $539000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 1.21 Mn |
| Dec 31, 2021 | -100,000.00 |
| Dec 31, 2020 | 539,000.00 |
| Dec 31, 2019 | -123,551.00 |
| Sep 30, 2019 | 3.00 Mn |
| Jun 30, 2019 | 2.99 Mn |
| Mar 31, 2019 | -5.90 Mn |
| Dec 31, 2018 | 2.00 Mn |
| Sep 30, 2018 | 3.66 Mn |
| Jun 30, 2018 | 3.25 Mn |
| Mar 31, 2018 | 3.00 Mn |
| Dec 31, 2017 | -3.06 Mn |
| Sep 30, 2017 | 3.00 Mn |
| Jun 30, 2017 | -10.02 Mn |
| Mar 31, 2017 | 710,335.00 |
| Dec 31, 2016 | 4.68 Mn |
| Sep 30, 2016 | -1.91 Mn |
| Jun 30, 2016 | 2.48 Mn |
| Mar 31, 2016 | -766,356.00 |
| Dec 31, 2015 | -4.28 Mn |